1JK Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Apellis Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 34.33 EUR -1.01% Market Closed

Market Cap: €4.2B

	Apellis Pharmaceuticals Inc F:1JK	US
	Monopar Therapeutics Inc F:1IY	US
M	Mitsubishi Estate Co Ltd DUS:MES	JP
S	Synopsys Inc F:SYP	US
	SoftBank Group Corp TSE:9984	JP
	Northisle Copper and Gold Inc F:0N4	CA
T	Telefonaktiebolaget LM Ericsson XMUN:ERCB	SE
N	NOW Inc F:11N	US
I	Imperial Oil Ltd AMEX:IMO	CA
T	Tessenderlo Group NV SWB:TEZ	BE
T	Telefonaktiebolaget LM Ericsson SWB:ERCB	SE
D	Dalipal Holdings Ltd HKEX:1921	CN
	Impala Platinum Holdings Ltd F:IPHB	ZA
	Soitec SA F:SOH1	FR
P	Ping An Insurance Group Co of China Ltd XMUN:PZX	CN

Profitability Summary

Apellis Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

90%

Strong 3Y Average Gross Margin

86%

Gross Margin is Increasing

88% > 90%

Low Operating Margin

Negative 3Y Average Operating Margin

-129%

Operating Margin is Increasing

-636% > 6%

Low Net Margin

Negative 3Y Average Net Margin

-134%

Net Margin is Increasing

-653% > 2%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-123%

Free Cash Flow Margin is Increasing

-549% > 4%

Low ROE

Negative 3Y Average ROE

Negative 3Y Average ROIC